Hayley Virgil

Senior Editor, OncLive®
Hayley Virgil heads OncLive's feature article efforts and specializes in social issues and equality in oncology. Prior to joining the company in early 2020, she worked as an editor in numerous industries, including media, marketing, hospitality, and computer science, and freelanced in subjects such as history, culture, and the natural sciences.

Articles

Frontline Immunotherapy Improves Survival in Advanced RCC, But Benefit to Be Determined for Favorable-Risk Subset

September 16th 2021

Frontline immunotherapy resulted in improved progression-free survival and overall survival compared with sunitinib in patients with advanced renal cell carcinoma; however, determining the benefit in those with favorable-risk disease must be examined further.

MRD-Based Consolidation Dara-KRd Elicits Rapid Responses in Newly Diagnosed Myeloma

September 11th 2021

Minimal residual disease–based consolidation therapy comprised of daratumumab, carfilzomib, lenalidomide, and dexamethasone was found to induce quick responses and unprecedented rates of MRD negativity in patients with newly diagnosed multiple myeloma.

Native American Ancestry Correlates With EGFR, KRAS Mutations in Lung Cancer

August 6th 2021

An association has been found in Latin American patients with lung adenocarcinoma between Native American ancestry and somatic landscape, including EGFR, KRAS, and STK11 mutations, as well as tumor mutational burden.

Low-Dose Venetoclax Achieves Promising Results in AL Amyloidosis and Myeloma Subsets

August 5th 2021

Low-dose venetoclax monotherapy demonstrated antitumor activity in patients with heavily pretreated multiple myeloma and light chain amyloidosis harboring t(11;14).

Soliman Details Ongoing Novel Immunotherapeutic Research Efforts at Moffitt, Recent Developments in Breast Cancer

August 2nd 2021

Moffitt Cancer Center is currently working to develop a host of novel therapeutic treatments within the breast cancer space, from immunotherapeutics to personalized cancer vaccines.

African Ancestry Is Linked With Higher Prostate Cancer Risk Vs European Ancestry

August 2nd 2021

Germline variation could play a role in racial disparities related to prostate cancer risk, with individuals of African descent having a higher mean genetic risk score compared with men of European ancestry.

Utility of Immunotherapy Keeps Evolving in Unresectable Stage III NSCLC

July 31st 2021

Many checkpoint inhibitors are currently under investigation in combination with concurrent radiotherapy in stage III non–small cell lung cancer, which experts propose could have practice-changing implications.

High Visceral Fat Index Associated With Worse Survival Outcomes in Early-Stage Lung Cancer

July 28th 2021

The method used to calculate how obesity is measured may impact whether it should be considered as a risk factor for non–small cell lung cancer.

Genomic Prostate Score Could Impact Treatment Decisions in Diverse Prostate Cancer Populations

July 27th 2021

The net effect of the Oncotype DX Genomic Prostate Score in patients with favorable-risk prostate cancer was to move away from active surveillance, altering the understanding of how prognostic molecular assays that generate probabilities of poor outcome can impact treatment decisions in diverse populations.

Disparities in Race and Socioeconomic Factors Linked With Outcomes in LS-SCLC

July 27th 2021

Racial minorities with limited-stage small cell lung cancer, including African American and Asian patients, were found to have more favorable survival outcomes compared with White patients, which suggests that race is associated with survival in this disease.

Surgery Plus Neoadjuvant Therapy Improves Survival in Margin-Positive Pancreatic Cancer

July 26th 2021

Surgical resection demonstrated a notable survival benefit, particularly in combination with neoadjuvant therapy, in patients with aggressive margin-positive pancreatic cancer.

Early Changes in ctDNA May Predict Response to CD19-Targeted CAR T-cell Therapy in LBCL

July 23rd 2021

Heterogeneity in the cellular and molecular features of CAR T-cell products contributes to variation in efficacy and toxicity follow treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma, and molecular response at day 7 might represent an early predictor of efficacy with this modality.

Examining Interventions to Increase Participation of Hispanic/Latinx Populations to Clinical Trials for Cancers

July 23rd 2021

Rodolfo Gutierrez, MD, discusses racial disparities in cancer care and interventions to encourage increased participation of the Hispanic and Latinx community on clinical trials.

Understanding Etiology of TNBC is Critical for Discovering Effective Preventive Approaches

July 22nd 2021

Mark E. Sherman, MD, discusses research efforts evaluating immune responses and risk of TNBC and implications for higher rates of disease among African American women.

Addition of Focal Boost to Intraprostatic Lesions in EBRT Improves Biochemical DFS in Localized Prostate Cancer

July 14th 2021

The addition of a focal boost to the intraprostatic lesion was found to improve biochemical disease-free survival in patients undergoing treatment with external beam radiotherapy for localized intermediate- and high-risk prostate cancer.

Eprenetapopt/Azacitidine Combo Elicits Promising Activity in TP53-Mutant MDS and AML

July 13th 2021

The combination of eprenetapopt and azacitidine demonstrated a promising safety profile as well as encouraging clinical activity in a high-risk population of patients with TP53-mutated myelodysplastic syndrome and acute myeloid leukemia.

New Potential Therapeutics, Including BT169, Open Options in Osteosarcoma

July 13th 2021

Richard Gorlick, MD, expands on the process of identifying these novel targets in osteosarcoma and the clinical implications of this research for these patients.

COVID-19 Vaccination Induces High Seroconversion Rates in Patients With Cancer, But Novel Strategies Needed for Select Subsets

July 8th 2021

Balazs Halmos, MD, MS, discusses a study examining the effectiveness of COVID-19 vaccination in patients with cancer and identified important areas for future research.

Enobosarm May Represent a Safe, New Hormone Treatment Approach for AR+, ER+ Metastatic Breast Cancer

July 6th 2021

Hannah M. Linden, MD, discusses the potential for enobosarm in patients with metastatic breast cancer, data from a phase 2 trial examining its use, and next steps for the agent in the paradigm.

Adjuvant Radiation Therapy Could Yield Reduction in All-Cause Mortality in High-Risk Prostate Cancer

July 6th 2021

Men with positive pelvic lymph nodes or a prostatectomy Gleason score of 8 to 10 with disease extending beyond the prostate should be considered for treatment with adjuvant radiation therapy.